ABUS - Arbutus Biopharma Corporation
| Previous Close | 9.10 |
| Open | 9.05 |
| Bid | 7.60 x 1800 |
| Ask | 9.05 x 3100 |
| Day's Range | 9.00 - 9.23 |
| 52 Week Range | 3.45 - 12.60 |
| Volume | 162,465 |
| Avg. Volume | 485,826 |
| Market Cap | 504.179M |
| Beta | 2.11 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.58 |
| Earnings Date | May 2, 2018 - May 7, 2018 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 9.32 |
- GlobeNewswire•5 days ago
Arbutus’ LNP Licensee Alnylam Announces FDA Approval of ONPATTRO™ (patisiran), for the Treatment of ATTR Amyloidosis
Arbutus Biopharma Corporation (ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, today announced that the Company's lipid nanoparticle (LNP) licensee, Alnylam Pharmaceuticals, Inc. (ALNY), announced that their new drug application (NDA) for ONPATTRO, an RNAi therapeutic, has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of hereditary ATTR amyloidosis with polyneuropathy. Because ONPATTRO is enabled by our proprietary LNP technology, this approval triggers a royalty to Arbutus and provides us with important non-dilutive revenue to support our HBV cure mission, through several important clinical milestones next year,” said Dr. Mark Murray, Arbutus’ President and CEO.
- GlobeNewswire•9 days ago
Arbutus to Present at the 2018 Wedbush PacGrow Healthcare Conference
WARMINSTER, Pa., Aug. 09, 2018-- Arbutus Biopharma Corporation, an industry-leading Hepatitis B Virus therapeutic solutions company, today announced that Dr. Michael Sofia, Arbutus’ Chief Scientific Officer, ...
- GlobeNewswire•16 days ago
Arbutus Reports 2018 Second Quarter Financial Results and Provides Corporate Update
-Phase 1 a/1b study of AB-506, a second-generation oral capsid inhibitor, initiated. -Phase 1 a/1b study of AB-452, a novel and proprietary oral RNA destabilizer, expected to begin in the second half of ...
- ACCESSWIRE•16 days ago
Arbutus Biopharma Corporation to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / August 2, 2018 / Arbutus Biopharma Corporation (NASDAQ: ABUS ) will be discussing their earnings results in their Q2 Earnings Call to be held on August 2, 2018 at 4:30 PM Eastern ...
Market Realist•25 days agoContraVir Stock Rose on Clinical Trial Progress Report
On July 23, ContraVir Pharmaceuticals stock closed at $0.95, which represents ~12% growth from its 52-week low of $0.85 on July 20 and 4.7% growth from its close of $0.91 on July 20. ContraVir Pharmaceuticals hit its 52-week high of $6.60 on October 17, 2017. On July 23, ContraVir Pharmaceuticals stock started rising after the company gave an update on its phase 1/2A trial of CRV431.
- Zacks•29 days ago
Arbutus Biopharma (ABUS) Shares March Higher, Can It Continue?
As of late, it has definitely been a great time to be an investor in Arbutus Biopharma Corporation (ABUS)
- MarketWatch•last month
Harry Boxer’s three drug stocks to watch
Drug stocks are dominating our list of top charts to watch. Arbutus Biopharma Corp. (ABUS) snapped back 55 cents to $11.35 on 417,300 shares traded Tuesday. Arrowhead Pharmaceuticals Inc. (ARWR) jumped 65 cents to $16.45 on 1 million shares traded Tuesday.
- GlobeNewswire•last month
Arbutus to Report Second Quarter 2018 Financial Results
WARMINSTER, Pa., July 19, 2018-- Arbutus Biopharma Corporation, an industry-leading Hepatitis B Virus therapeutic solutions company, today announced that it has scheduled its second quarter financial results, ...
- Motley Fool•last month
3 Biotech Stocks That Soared This Week: Are They Buys?
Can these hot biotech stocks get even hotter?
- MarketWatch•last month
Harry Boxer’s four health-care stocks to watch
In focus: Arbutus Biopharma, Marinus Pharmaceuticals, Neptune Technologies & Bioressources and OPKO Health.
- GlobeNewswire•last month
Arbutus Presents Corporate Update on Key Milestones
The first subject has been dosed in a clinical trial of AB-506, Arbutus’ second-generation capsid inhibitor. The regulatory filing for AB-452, Arbutus’ novel and proprietary RNA destabilizer, is on track for submission in Q3, with subject dosing to follow in Q4. Study completion is expected by Q3 2019.
- Motley Fool•last month
3 Biotech Stocks That Soared This Week: Are They Buys?
Can these hot biotech stocks keep the momentum going?
- Benzinga•last month
Analyst Downgrades Arbutus Biopharma On Valuation After 80% Run
Arbutus Biopharma Corp (NASDAQ: ABUS ) stock has gained 80 percent since the turn of the year, and B. Riley FBR dropped its bullish stance Friday in the wake of the rally. The Analyst B. Riley FBR's ...
- Zacks•last month
Arbutus Biopharma (ABUS) Jumps: Stock Rises 9.6%
Arbutus Biopharma (ABUS) was a big mover last session, as the company saw its shares rise more than 9% on the day, amid huge volumes.
- GlobeNewswire•2 months ago
Arbutus Biopharma to Present at First Annual Roivant Pipeline Day
Arbutus Biopharma Corporation (ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, today announced that it will present at the first annual Roivant Pipeline Day on July 10, 2018, at 4:00 p.m. ET. A live webcast will be available via the Investors section, under Events and Presentations of Arbutus' website at www.arbutusbio.com. Please connect to the company's website at least 15 minutes prior to the presentation to ensure adequate time for any software download that may be required to listen to the webcast. Roivant Pipeline Day will be held on Tuesday, July 10, 2018, in New York City.
- GlobeNewswire•2 months ago
Arbutus Strengthens Management Team With Appointment of David C. Hastings as New Chief Financial Officer
Arbutus Biopharma Corporation (ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, today announced the appointment of David Hastings as Chief Financial Officer, effective June 11, 2018. Mr. Hastings will assume the CFO role from Koert VandenEnden, Arbutus' interim Chief Financial Officer. "We’re excited to welcome David Hastings to Arbutus as our new CFO," said Dr. Mark J Murray, CEO of Arbutus.
- GlobeNewswire•2 months ago
Research Report Identifies Diodes, Arbutus Biopharma, Radware, Immutep, Amarin, and SPS Commerce with Renewed Outlook — Fundamental Analysis, Calculating Forward Movement
NEW YORK, June 06, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Diodes ...
- ACCESSWIRE•3 months ago
Blog Exposure - Spectrum Pharma Inked Licensing Agreement with The University of Texas MD Anderson Cancer Center on Certain Methods of Use of Poziotinib
LONDON, UK / ACCESSWIRE / May 07, 2018 / If you want access to our free research report on Spectrum Pharma, Inc. (NASDAQ: SPPI), all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=SPPI as the Company's latest news hit the wire. On May 03, 2018, the Company announced that it has inked an exclusive licensing agreement with The University of Texas MD Anderson Cancer Center for intellectual property related to exon 20 and certain methods of use of poziotinib. Active-Investors.com is currently working on the research report for Arbutus Biopharma Corporation (NASDAQ: ABUS), which also belongs to the Healthcare sector as the Company Spectrum Pharma.
- Associated Press•4 months ago
Arbutus: 1Q Earnings Snapshot
The Burnaby, British Columbia-based company said it had a loss of 36 cents per share. The results surpassed Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment ...
